Business Context and Reporting Period
This Form 8-K Current Report was filed by Voyager Therapeutics, Inc. (VYGR) on April 21, 2026, covering events occurring on April 15, 2026, and April 20, 2026. The filing addresses significant changes in the Company's executive leadership regarding its financial officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation of CFO: Nathan Jorgensen, Ph.D., resigned as Chief Financial Officer and from all other positions effective May 8, 2026. The resignation is voluntary to pursue a new opportunity and is not the result of any disagreement with the Company.
- Appointment of Principal Financial Officer: Robin Swartz was appointed as Principal Financial Officer and Treasurer, effective May 8, 2026. Ms. Swartz previously served as Chief Operating Officer and Chief Business Officer.
- Appointment of Principal Accounting Officer: Amy Quinlan was appointed as Principal Accounting Officer, effective May 8, 2026. Ms. Quinlan has served as Vice President of Finance since January 2025.
Outlook, Risks, and Unusual Items
The filing confirms a smooth transition plan for the financial leadership roles. There are no reported disagreements, litigation, or unusual items associated with the departure of Dr. Jorgensen. Ms. Quinlan is expected to enter into the Company's standard form of indemnification agreement, which may require the Company to indemnify her for certain expenses incurred in her service as an officer.
Investor Verification Checklist
- Verify the effective date of the leadership transition (May 8, 2026) and confirm interim financial reporting responsibilities.
- Review Ms. Swartz's and Ms. Quinlan's biographies to assess their experience relative to the Company's current financial and operational needs.
- Confirm that no undisclosed disagreements or disputes exist regarding the CFO's departure.
- Monitor upcoming quarterly filings for any impact on financial reporting timelines or internal controls due to the leadership change.